FDA Panel Backs Galleri Blood Test That Misses 69% of Cancers
GRAIL's Galleri test screens 50-plus cancers from one blood draw, but missed 69% of cases and showed no mortality benefit — and an FDA panel backed it anyway.
Topic
FDA Approval
Topic
FDA Approval
Grail's Galleri Screens for 50 Cancers. Insurers Won't Pay Yet
Grail's Galleri test screens for 50 cancers from one blood draw, but a major study failed to prove detection of later-stage cance…
Eight Sleep Launches Pod 6 From $1,999 as FDA Bid Advances
Eight Sleep's Pod 6 starts at $1,999 with a 50% smaller footprint and 9x more sensors, sold in 37 countries as the firm pursues F…